Engineering
Chemicals
Biotechnology

Amyris

$3.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-4.51%) Today
-$0.09 (-2.24%) After Hours

Why Robinhood?

You can buy or sell Amyris and other stocks, options, ETFs, and crypto commission-free!

About

Amyris, Inc. Common Stock, also called Amyris, is an industrial biotechnology company, which engages in the provision of bioscience solutions. Read More It focuses on the research, development, manufacture, and sale of fuels and farnesene-derived products. Its products include cosmetics, flavors and fragrances, performance materials, diesel, jet fuel, and lubricants. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Employees
Headquarters
Emeryville, California
Founded
2003
Market Cap
257.64M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.91M
High Today
$4.27
Low Today
$3.98
Open Price
$4.22
Volume
593.56K
52 Week High
$9.29
52 Week Low
$1.87

Collections

Engineering
Chemicals
Biotechnology
Cosmetics
Materials
Health
Retail
US

News

Yahoo FinanceMay 22

Zhang Investor Law Reminds Investors of June 3 Deadline in Securities Class Action Lawsuit Against Amyris, Inc. - AMRS

NEW YORK, NY / ACCESSWIRE / May 22, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Amyris, Inc.

47
Yahoo FinanceMay 21

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Amyris, Inc. Investors

RADNOR, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Amyris, Inc. (Nasdaq: AMRS) (“Amyris”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Amyris on behalf of those who purchased or otherwise acquired Amyris securities between March 15, 2018 and March 19, 2019, inclusive (the “Class Period”). Important Deadline Reminder: Investors who purchased Amy...

142
Seeking AlphaMay 21

Amyris BioDisrupt 2019 - The Good, The Bad, And The Noise

Last week, I attended the annual investment day, BioDisrupt, at the Amyris (AMRS) headquarters in Emeryville. Unless otherwise cited, all of the numbers below are taken from the talks at the event, which can be viewed here. There were some good news, some bad news, and some inconsequential news, which still are likely to become talking points for investors. I attempt to sort the news into the "Good", "Bad", and "Noise" buckets below. The Good Production. Amyris signed a deal with Raízen to build two new p...

348

Earnings

-$0.81
-$0.34
$0.14
$0.61
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.42 per share
Actual
Expected May 31

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.